Hodgkin Lymphoma
Conference Coverage
Nivolumab produces ‘dramatic’ responses in HL
Photo courtesy of UCLA LUGANO—The PD-1 checkpoint inhibitor nivolumab produces rapid, durable, and, in some cases, “dramatic” responses in...
Conference Coverage
Bleomycin can be safely omitted after negative PET2 in HL
Photo by Jens Maus LUGANO—Results of the RATHL trial indicate that bleomycin can be omitted from ABVD therapy following a negative interim FDG-...
News
Alisertib shows activity in non-Hodgkin lymphoma
Key clinical point: Alisertib has shown significant antitumor activity in patients with relapsed or refractory peripheral T-cell non-Hodgkin...
News
Prenatal test can detect lymphoma in mothers
Photo by Graham Colm GLASGOW—A non-invasive prenatal test (NIPT) used to identify chromosomal fetal disorders can detect maternal cancers before...
News
Hodgkin lymphoma incidence on the decline worldwide
Photo courtesy of NIH In trying to estimate the global cancer burden, researchers found that cases of Hodgkin lymphoma (HL) have decreased...
News
CAR T-cell therapy appears feasible in HL
LONDON—Results of a small, phase 1 trial suggest CD30-directed chimeric antigen receptor (CAR) T-cell therapy is feasible in patients with...
News
Symptoms confer higher-than-expected risk of HL, NHL
Results from two new studies indicate that lymphadenopathy and head and neck masses are associated with a higher risk of lymphoma than we thought...
Conference Coverage
Susceptibility to 2nd cancers in WM/LPL survivors
PHILADELPHIA—A retrospective study has revealed factors that appear to influence a person’s susceptibility to Waldenström’s macroglobulinemia (WM...
News
HL survivors have long-term risk of cardiovascular disease
Photo by Rhoda Baer Survivors of Hodgkin lymphoma (HL) have an increased risk of developing cardiovascular diseases throughout their lives,...
News
PET scans could prevent unnecessary RT in HL
Image by Jens Langner Performing PET scans immediately after chemotherapy may reveal which Hodgkin lymphoma (HL) patients need radiotherapy (RT...
News
ABVD and Stanford V similar for bulky mediastinal Hodgkin’s lymphoma
Key clinical point: No significant differences in outcomes were observed after treatment with ABVD vs. Stanford V in patients with stage I or II...